Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Assets (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Assets for 6 consecutive years, with $228.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets fell 38.35% to $228.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $228.8 million, a 38.35% decrease, with the full-year FY2025 number at $228.8 million, down 38.35% from a year prior.
  • Assets was $228.8 million for Q4 2025 at TScan Therapeutics, down from $262.2 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $374.9 million in Q2 2024 to a low of $130.0 million in Q2 2021.
  • A 5-year average of $248.4 million and a median of $240.8 million in 2024 define the central range for Assets.
  • Peak YoY movement for Assets: surged 278.2% in 2021, then crashed 38.35% in 2025.
  • TScan Therapeutics' Assets stood at $188.1 million in 2021, then increased by 5.84% to $199.1 million in 2022, then soared by 36.7% to $272.1 million in 2023, then surged by 36.37% to $371.1 million in 2024, then plummeted by 38.35% to $228.8 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Assets are $228.8 million (Q4 2025), $262.2 million (Q3 2025), and $298.6 million (Q2 2025).